Celgene profit rises 25 pct up on higher cancer drug sales

July 24 Thu Jul 24, 2014 7:50am EDT

July 24 (Reuters) - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.

The U.S. biotechnology company's net profit rose to $597.8 million, or 72 cents per share, in the second quarter ended June 30, from $478.1 million, or 56 cents per share, a year earlier.

Excluding special items, it earned 90 cents per share.

Total revenue rose 17 percent to $1.87 billion.

Sales of multiple myeloma treatment Revlimid rose 15 percent to $1.21 billion. (Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.